Literature DB >> 23893237

Blood stasis syndrome of coronary heart disease: A perspective of modern medicine.

Gui Yu1, Jie Wang2.   

Abstract

The medical community as a whole is attempting to start preventive therapy for coronary heart disease (CHD) patients earlier in life. However, the main limitations of such interventions are drug resistance and adverse reactions. Additionally, traditional biomarker discovery methods for CHD focus on the behavior of individual biomarkers regardless of their relevance. These limitations have led to attempting novel approaches to multi-dimensionally investigate CHD and identify safe and efficacious therapies for preventing CHD. Recently, the benefit of Chinese medicine (CM) in CHD has been proven by increasing clinical evidence. More importantly, linking CM theory with modern biomedicine may lead to new scientific discoveries. According to CM theory, all treatments for patients should be based on patients' syndromes. A recent epidemiological investigation has demonstrated that blood stasis syndrome (BSS) is the major syndrome type of CHD. BSS is a type of complex pathophysiological state characterized by decreased or impeded blood flow. Common clinical features of BSS include a darkish complexion, scaly dry skin, and cyanosis of the lips and nails, a purple or dark tongue with purple spots, a thready and hesitant pulse, and stabbing or pricking pain fixed in location accompanied by tenderness, mass formation and ecchymosis or petechiae. The severity of BSS is significantly correlated with the complexity of coronary lesions and the degree of stenosis, and is an important factor affecting the occurrence of restenosis after percutaneous coronary intervention. The mechanisms of BSS of CHD patients should be investigated from a modern medicine perspective. Although many studies have attempted to explore the biomedical mechanisms of BSS of CHD, from hemorheological disorders to inflammation and immune responses, the global picture of BSS of CHD is still unclear. In this article, the current status of studies investigating the biomedical mechanisms of BSS of CHD and future perspectives are discussed.

Entities:  

Keywords:  blood stasis syndrome; coronary heart disease; modern medicine

Mesh:

Year:  2013        PMID: 23893237     DOI: 10.1007/s11655-013-1332-3

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  33 in total

1.  Effect of Xuefu Zhuyu Capsule (血府逐瘀胶囊) on the symptoms and signs and health-related quality of life in the unstable angina patients with blood-stasis syndrome after percutaneous coronary intervention: A Randomized controlled trial.

Authors:  Fu-yong Chu; Jie Wang; Kui-wu Yao; Zhi-zhong Li
Journal:  Chin J Integr Med       Date:  2010-06-10       Impact factor: 1.978

Review 2.  Chinese integrative medicine: translation toward person-centered and balanced medicine.

Authors:  Xue-Gang Sun; Wei-Kang Wu; Zhi-Ping Lu
Journal:  Chin J Integr Med       Date:  2012-01-10       Impact factor: 1.978

3.  The rise of cardiovascular medicine.

Authors:  Eugene Braunwald
Journal:  Eur Heart J       Date:  2012-03-12       Impact factor: 29.983

Review 4.  Research progress on mechanism of action of Radix Astragalus in the treatment of heart failure.

Authors:  Qing-You Yang; Ke-Ji Chen; Shu Lu; Hui-Ru Sun
Journal:  Chin J Integr Med       Date:  2012-04-02       Impact factor: 1.978

Review 5.  End-organ dysfunction and cardiovascular outcomes: the role of the microcirculation.

Authors:  Christopher J Lockhart; Paul K Hamilton; Cathy E Quinn; Gary E McVeigh
Journal:  Clin Sci (Lond)       Date:  2009-02       Impact factor: 6.124

6.  Differential associations between soluble cellular adhesion molecules and atherosclerosis in the Dallas Heart Study: a distinct role for soluble endothelial cell-selective adhesion molecule.

Authors:  Anand Rohatgi; Andrew W Owens; Amit Khera; Colby R Ayers; Kamakki Banks; Sandeep R Das; Jarett D Berry; Darren K McGuire; James A de Lemos
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-10       Impact factor: 8.311

7.  Integrating traditional medicine with biomedicine towards a patient-centered healthcare system.

Authors:  Hao Xu; Ke-Ji Chen
Journal:  Chin J Integr Med       Date:  2011-02-10       Impact factor: 1.978

8.  Analysis on outcome of 5284 patients with coronary artery disease: the role of integrative medicine.

Authors:  Zhu-ye Gao; Hao Xu; Da-zhuo Shi; Chuan Wen; Bao-yan Liu
Journal:  J Ethnopharmacol       Date:  2011-09-08       Impact factor: 4.360

9.  A multi-center randomized double-blind placebo-controlled trial of Xiongshao Capsule in preventing restenosis after percutaneous coronary intervention: a subgroup analysis of senile patients.

Authors:  Qing-hua Shang; Hao Xu; Xiao-yan Lu; Chuan Wen; Da-zhuo Shi; Ke-ji Chen
Journal:  Chin J Integr Med       Date:  2011-09-11       Impact factor: 1.978

Review 10.  Aspirin resistance: effect of clinical, biochemical and genetic factors.

Authors:  Richard Fitzgerald; Munir Pirmohamed
Journal:  Pharmacol Ther       Date:  2011-02-02       Impact factor: 12.310

View more
  9 in total

Review 1.  Systematic review on randomized controlled trials of coronary heart disease complicated with depression treated with Chinese herbal medicines.

Authors:  An-Lu Wang; Zhuo Chen; Jing Luo; Qing-Hua Shang; Hao Xu
Journal:  Chin J Integr Med       Date:  2015-06-18       Impact factor: 1.978

2.  Expert opinions on the concept of blood stasis in China: An interview study.

Authors:  Tae-Young Choi; Ji Hee Jun; Ju Ah Lee; Bongki Park; Sooseong You; Jeeyoun Jung; Myeong Soo Lee
Journal:  Chin J Integr Med       Date:  2014-09-02       Impact factor: 1.978

3.  Multifactor dimensionality reduction analysis of the correlation of Chinese medicine syndrome evolvement and cardiovascular events in patients with stable coronary heart disease.

Authors:  Yang Jiao; Si-wei Li; Qing-hua Shang; Chang-geng Fu; Zhu-ye Gao; Hao Xu; Da-zhuo Shi; Ke-ji Chen
Journal:  Chin J Integr Med       Date:  2014-03-06       Impact factor: 1.978

4.  Exploring the mechanism of Shengmai Yin for coronary heart disease based on systematic pharmacology and chemoinformatics.

Authors:  Yan Jiang; Qi He; Tianqing Zhang; Wang Xiang; Zhiyong Long; Shiwei Wu
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

5.  The efficacy of Yiqi Huoxue method in treating coronary artery disease after percutaneous coronary intervention: A meta-analysis in accordance with PRISMA guideline.

Authors:  Miao Zhang; Ming-Yue Sun; Qi-Ting Chen; Feng-Qin Xu; Zong-Zheng Chen; Wen-Bo Wei; Rui-Ting Wang; Gui-Peng Xu; Hui-Jun Yin
Journal:  Medicine (Baltimore)       Date:  2022-10-14       Impact factor: 1.817

Review 6.  Modern researches on Blood Stasis syndrome 1989-2015: A bibliometric analysis.

Authors:  Jiangquan Liao; Jie Wang; Yongmei Liu; Jun Li; Lian Duan; Guang Chen; Junyuan Hu
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.817

Review 7.  Effectiveness and Safety of Compound Chinese Medicine plus Routine Western Medicine in In-Stent Restenosis: A Meta-Analysis and Systematic Review.

Authors:  Lu Liu; Jing Liu; Qun Gao; Yang Wu; Jinjin Lu; Jie Wan; Yan Li; Xiaoyun Cui; Kun Zhou; Wenhao Jia; Yanchao Huang; Wenbai Qu; Qian Lin
Journal:  Evid Based Complement Alternat Med       Date:  2018-07-11       Impact factor: 2.629

8.  Jiawei Foshou San Induces Apoptosis in Ectopic Endometrium Based on Systems Pharmacology, Molecular Docking, and Experimental Evidence.

Authors:  Jiahui Wei; Binxin Zhao; Chengling Zhang; Bingbing Shen; Ying Zhang; Changxi Li; Yi Chen
Journal:  Evid Based Complement Alternat Med       Date:  2019-10-27       Impact factor: 2.629

9.  A randomized controlled trial for gualou danshen granules in the treatment of unstable angina pectoris patients with phlegm-blood stasis syndrome.

Authors:  Jianbo Guo; Shuang Dai; Yukun Ding; Haoqiang He; Hui Zhang; Wenchao Dan; Kun Qin; Hui Wang; Anqi Li; Peipei Meng; Shangjin Li; Qingyong He
Journal:  Medicine (Baltimore)       Date:  2020-08-14       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.